Farhan Raza, MD

Education

• King Edward Medical University, Lahore, Pakistan - MD
• Temple University Hospital, Philadelphia, Pennsylvania - Residency in Internal Medicine
• Temple Heart and Vascular Institute, Philadelphia, Pennsylvania - Fellowship in Cardiovascular Disease
• Temple Heart and Vascular Institute - Chief Cardiology Fellow
• Temple Heart and Vascular Institute - Research Fellow, Pulmonary Hypertension
• Weill Cornell Medical Center/New York Presbyterian Hospital, New York - Fellowship in Pulmonary Hypertension, Advanced Heart Failure and Heart Transplant

Professional Activities

Dr. Farhan Raza is a faculty member in the Division of Cardiovascular Medicine within the Department of Medicine. He received his medical education from King Edward Medical University, Pakistan, and completed his residency training in Internal Medicine at Temple University Hospital in Philadelphia, Pennsylvania. He completed fellowships in Cardiovascular Disease at Temple Heart and Vascular Institute in Philadelphia. He also completed a fellowship in Pulmonary Hypertension, Advanced Heart Failure and Transplant. He has presented his clinical research findings at multiple national and international conferences.

Clinical Specialties

Dr. Raza's clinical interests include clinical management of pulmonary hypertension of wide variety of etiologies including pulmonary arterial hypertension, connective tissue disease like scleroderma, chronic thromboembolic disease and pulmonary hypertension related to left heart disease. His clinical expertise also includes advanced heart failure including left ventricular assist device (LVAD) technology and cardiac transplant, echocardiography, and infiltrative cardiomyopathies such as amyloidosis and sarcoidosis.

Research Interests

View Dr. Raza’s publications on NCBI MyBibliography

Dr. Raza's research focuses on deep phenotyping methods of HFpEF and pulmonary hypertension, including bioengineering exercise hemodynamic analyses, cardiac MRI and Omics approach (myocardial tissue and serum). His overall goals are mechanistic phenotype driven targeted therapies to improve patient outcomes.